Over 80 million people in the United States exhibit pain and discomfort from gastroesophageal reflux at least once per month, and 60 percent of the adult population will experience some type of gastroesophageal reflux disease within a 12-month period. Providers often prescribe proton pump inhibitor therapy to treat GERD. However, many patients do not respond to PPIs therapy, and recent studies have shown the Transoral Incisionless Fundoplication (TIF) procedure (with EsophyX device) can not only reduce GERD symptoms, but can eliminate the need for some patients to stop using PPIs medications controlling symptoms up to three years.
“There is a reason PPIs fails,” says Anthony D. Starpoli, associate director of esophageal endotherapy; Lenox Hill Hospital, New York; clinical instructor department of medicine, NYU Langone Medical Center; and attending gastroenterology, Mt. Sinai Beth Israel Medical Center, New York. “It does not treat regurgitation, which is a mechanical problem.”
Read more at Becker’s ASC–A Game Changer for GI